Skip to main
  1. Stocks
  2. Penumbra
  3. Forecast
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra is positioned for attractive fundamental growth because its Thunderbolt FDA clearance on 6/11 makes it the only approved stroke CAVT device in the U.S., expanding its leadership in acute ischemic stroke with a first-of-its-kind platform that may improve clot removal speed and completeness. The company also benefits from a broad, under-penetrated addressable market, including a US vascular TAM of $2.7B, more than +1MM intervention patients, and a neuro/vascular portfolio that supports sustained double-digit revenue growth through product innovation. With OUS revenues at ~29% of 2024 and high-single-digit CAGR expected through 2030, Penumbra’s differentiated technology, premium pricing potential, and international expansion create a compelling long-term outlook.

Bears say

Penumbra is vulnerable because its acute ischemic stroke growth depends on a broad shift from stent retrievers to aspiration therapy, yet the evidence base remains device-agnostic and may not prove superior functional outcomes for its approach. It also faces entrenched competition from Medtronic, Stryker, Boston Scientific, Johnson & Johnson, and Terumo, whose greater scale and pricing power could pressure share and margins while continued innovation and regulatory approvals remain essential to growth. Although favorable U.S. reimbursement currently supports the business, any reimbursement deterioration, product launch missteps, supply chain disruption, litigation, or deferred procedures could quickly impair execution and valuation.

Penumbra (PEN) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Penumbra (PEN) Analyst Forecast & Price Prediction

Get the latest Penumbra (PEN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Penumbra (PEN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Hold based on their latest research and market trends.

According to 13 analysts, Penumbra (PEN) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $366.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $366.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Penumbra (PEN) Analyst Forecast & Price Prediction

Get the latest Penumbra (PEN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Penumbra (PEN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PEN stock data and trends